| Literature DB >> 24646665 |
Abhay Lodha1, Reg Sauvé1, Vineet Bhandari2, Selphee Tang3, Heather Christianson4, Anita Bhandari5, Harish Amin6, Nalini Singhal7.
Abstract
OBJECTIVES: To determine if chronic oxygen dependency (discharge home on supplemental oxygen) in children with bronchopulmonary dysplasia (BPD; defined as requirement for supplemental O2 at 36 weeks postmenstrual age) predicts neurodevelopmental disability rates and growth outcomes at 36 months corrected age (CA). STUDYEntities:
Mesh:
Substances:
Year: 2014 PMID: 24646665 PMCID: PMC3960119 DOI: 10.1371/journal.pone.0090843
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Discharge criteria of infant from NICU.
| Criteria |
| a. Corrected gestational age >34 weeks |
| b. Able to maintain body temperature (>36.4°C) in an open crib |
| c. Competent suckle feeding (breast or bottle) without cardiorespiratory compromise and gaining weight |
| d. Physiologically mature |
| e. Stable cardiorespiratory function |
| f. No apnea of prematurity |
| g. No active medical problems |
| h. Receipt of appropriate immunizations |
| i. Appropriate metabolic screening and car seat testing performed |
| j. In addition to the above criteria, family readiness |
Figure 1Flow diagram of the study cohort.
Characteristics of the Follow-up Cohort and Their Mothers.
| Characteristic | No BPD | BPD | BPD withchronic oxygendependency | p-value | Confidence Intervals forPairwise Differences | ||
| Infants | (n = 442) | (n = 144) | (n = 444) | No BPDvs. BPD | No BPD vs. BPDwith chronicoxygen dependency | BPD vs. BPDwith chronicoxygen dependency | |
| Birth weight-grams, median (IQR) | 1070 (930, 1180) | 885 (750, 1060) | 820 (690, 1000) | <0.001 | (90 to 180) | (180 to 245) | (20 to 120) |
| Gestational age -wk, median (IQR) | 29 (27, 30) | 27 (26, 28) | 26 (25, 28) | <0.001 | (1 to 2) | (2 to 3) | (0 to 1) |
| Gestational age at discharge-wk, median (IQR) | 37 (35, 38) | 40 (38, 41) | 39 (37, 41) | <0.001 | (−4 to −2) | (−3 to −2) | (0 to 1) |
| Male sex, no. (%) | 201 (45.5) | 68 (47.2) | 256 (57.7) | <0.001 | (−0.13 to 0.10) | (−0.20 to −0.04) | (−0.22 to 0.01) |
| Singleton, no. (%) | 311 (70.4) | 90 (62.5) | 317 (71.4) | 0.121 | (−0.03 to 0.19) | (−0.08 to 0.06) | (−0.20 to 0.02) |
| Inborn, no. (%) | 396 (89.6) | 124 (86.1) | 391 (88.1) | 0.496 | (−0.04 to 0.11) | (−0.04 to 0.07) | (−0.10 to 0.06) |
| Small for gestational age (<10th %ile), no. (%) | 95 (21.5) | 18 (12.5) | 70 (15.9) | 0.019 | (0.01 to 0.17) | (−0.01 to 0.12) | (−0.11 to 0.04) |
| Surfactant, no. (%) | 168 (38.2) | 95 (66.0) | 333 (75.2) | <0.001 | (−0.39 to −0.17) | (−0.44 to −0.30) | (−0.20 to 0.01) |
| Positive pressure ventilation, (CMV+HFO) no. (%) | 250 (56.6) | 133 (92.4) | 424 (95.5) | <0.001 | (−0.44 to −0.28) | (−0.45 to −0.33) | (−0.09 to 0.03) |
| NCPAP, no. (%) | 170 (38.5) | 107 (74.3) | 368 (82.9) | <0.001 | (−0.46 to −0.26) | (−0.51 to −0.37) | (−0.18 to 0.01) |
| Hospital stay-days, median (IQR) | 56 (43, 71) | 93 (76, 103) | 92 (74, 109) | <0.001 | (−39 to −30) | (−39 to −32) | (−7 to 4) |
| Total ventilation-days, median (IQR) | 1 (0, 6) | 21 (8, 39) | 36 (18, 52) | <0.001 | (−20 to −12) | (−34 to −27) | (−17 to −6) |
| Total suppl. oxygen-days, median (IQR) | 6 (2, 37) | 78 (62, 93) | 209 (153, 277) | <0.001 | (−68 to −56) | (−200 to −177) | (−144 to −112) |
| Total blood transfusions-times, median (IQR) | 0 (0, 1) | 3 (1, 4) | 4 (2, 6) | <0.001 | (−3 to −2) | (−4 to −3) | (−2 to 0) |
| Postnatal steroids, no. (%) | 21 (4.8) | 29 (20.3) | 144 (32.5) | <0.001 | (−0.24 to −0.07) | (−0.34 to −0.22) | (−0.22 to −0.03) |
| Diuretics, no. (%) | 139 (31.6) | 114 (79.7) | 384 (86.5) | <0.001 | (−0.58 to −0.38) | (−0.61 to −0.48) | (−0.16 to 0.02) |
| Patent ductus arteriosus, no. (%) | 117 (26.5) | 89 (61.8) | 307 (69.3) | <0.001 | (−0.46 to −0.24) | (−0.50 to −0.36) | (−0.19 to 0.04) |
| Respiratory distress syndrome, no. (%) | 224 (50.7) | 123 (85.4) | 386 (87.1) | <0.001 | (−0.44 to −0.26) | (−0.43 to −0.30) | (−0.10 to 0.06) |
| Confirmed sepsis, no. (%) | 42 (9.7) | 39 (27.3) | 110 (25.0) | <0.001 | (−0.27 to −0.08) | (−0.21 to −0.09) | (−0.08 to 0.12) |
| Necrotizing enterocolitis, no. (%) | 40 (9.1) | 24 (16.7) | 54 (12.2) | 0.037 | (−0.16 to 0.01) | (−0.08 to 0.02) | (−0.04 to 0.13) |
| Intraventricular hemorrhage grade ≥ III, no. (%) | 10 (2.3) | 11 (7.7) | 41 (9.2) | <0.001 | (−0.11 to 0.002) | (−0.11 to −0.03) | (−0.08 to 0.05) |
| Periventricular leukomalacia, no. (%) | 10 (2.3) | 6 (4.2) | 7 (1.6) | 0.196 | (−0.06 to 0.02) | (−0.02 to 0.03) | (−0.02 to 0.07) |
| Retinopathy of prematurity stage ≥III, no. (%) | 14 (3.6) | 28 (20.4) | 119 (28.0) | <0.001 | (−0.25 to −0.08) | (−0.30 to −0.19) | (−0.17 to 0.02) |
|
| |||||||
| Maternal education more than high school, no. (%) | 252 (60.9) | 79 (57.3) | 253 (59.8) | 0.753 | (−0.08 to 0.15) | (−0.09 to 0.07) | (−0.14 to 0.09) |
| Single parent, no. (%) | 29 (6.6) | 7 (4.9) | 29 (6.6) | 0.735 | (−0.03 to 0.07) | (−0.04 to 0.04) | (−0.07 to 0.03) |
| Blishen score, median (IQR) | 41 (33, 56) | 46 (33, 57) | 44 (33, 57) | 0.227 | (−6 to 1) | (−4 to 1) | (−3 to 4) |
| Maternal race Caucasian, no. (%) | 274 (70.8) | 93 (79.5) | 280 (77.6) | 0.047 | (−0.19 to 0.02) | (−0.14 to 0.01) | (−0.08 to 0.12) |
| Maternal antihypertensive, no. (%) | 101 (23.2) | 14 (10.3) | 75 (17.3) | 0.002 | (0.05 to 0.21) | (−0.01 to 0.12) | (−0.15 to 0.01) |
| Smoking during pregnancy, no. (%) | 121 (28.3) | 39 (27.7) | 102 (23.8) | 0.302 | (−0.10 to 0.11) | (−0.03 to 0.12) | (−0.06 to 0.14) |
| Antenatal corticosteroids, no. (%) | 378 (86.7) | 116 (82.9) | 366 (83.8) | 0.367 | (−0.05 to 0.12) | (−0.03 to 0.09) | (−0.10 to 0.08) |
| Maternal antibiotics, no. (%) | 247 (57.2) | 84 (60.4) | 262 (60.5) | 0.572 | (−0.15 to 0.08) | (−0.11 to 0.05) | (−0.11 to 0.11) |
| Chorioamnionitis, no. (%) | 94 (22.3) | 37 (27.4) | 93 (21.5) | 0.354 | (−0.15 to 0.05) | (−0.06 to 0.08) | (−0.04 to 0.16) |
| Caesarean section, no. (%) | 303 (68.7) | 94 (65.3) | 246 (55.5) | <0.001 | (−0.07 to 0.14) | (0.05 to 0.21) | (−0.01 to 0.21) |
Kruskal-Wallis test for continuous variables; Pearson χ2 test for categorical variables.
*Bonferroni correction applied to adjust for the three pairwise comparisons, thus confidence intervals are reported at the (1–0.05/3) % level.
BPD: bronchopulmonary dysplasia; CMV: conventional mechanical ventilation; HFO: high frequency oscillatory ventilation; NCPAP: nasal continuous airways pressure.
Figure 2Growth parameters (weight, height and head circumference) in the No BPD, BPD and BPD with chronic oxygen dependency groups at 36 months corrected age.
Growth at 36 months corrected age.
| No BPD | BPD | BPD with chronic oxygen dependency | p-value | |
| Growth Parameter | (n = 409/442) | (n = 139/144) | (n = 407/444) | |
| Weight z-score, mean (SD) | −0.64 (1.1) | −0.83 (1.6) | −0.81 (1.3) | 0.082 |
| Height z-score, mean (SD) | −0.30 (1.0) | −0.47 (1.1) | −0.46 (1.2) | 0.078 |
| Head circumference z-score, mean (SD) | −0.08 (1.0) | −0.07 (1.2) | −0.11 (1.1) | 0.892 |
*ANOVA F-test. Welch’s ANOVA F-test reported if variances were non-homogeneous according to Levene’s test.
BPD: bronchopulmonary dysplasia.
Disability Status at 36 Months Corrected Age (No., %).
| No BPD | BPD | BPD with chronic oxygen dependency | |||
| Disability Type | Disability Severity | n = 442 | n = 144 | n = 444 | p-value |
| Cerebral Palsy | None | 418 (94.6) | 127 (88.2) | 396 (89.2) | 0.033 |
| Mild | 10 (2.3) | 6 (4.2) | 17 (3.8) | ||
| Moderate-Severe | 14 (3.2) | 11 (7.6) | 31 (7.0) | ||
| Blindness | None | 422 (96.1) | 133 (93.0) | 395 (89.6) | <0.001 |
| Visual Disability | 15 (3.4) | 10 (7.0) | 34 (7.7) | ||
| Legally Blind | 2 (0.5) | 0 (0.0) | 12 (2.7) | ||
| Deafness | None | 438 (99.8) | 140 (97.9) | 417 (94.6) | <0.001 |
| Hearing Disability | 1 (0.2) | 2 (1.4) | 5 (1.1) | ||
| Deaf | 0 (0.0) | 1 (0.7) | 19 (4.3) | ||
| Cognitive Function | Normal | 372 (84.9) | 110 (76.9) | 307 (69.9) | <0.001 |
| Borderline | 44 (10.1) | 19 (13.3) | 78 (17.8) | ||
| Delay | 22 (5.0) | 14 (9.8) | 54 (12.3) | ||
| Any Disability | None | 343 (79.4) | 93 (65.5) | 254 (58.3) | <0.001 |
| Mild | 62 (14.4) | 27 (19.0) | 102 (23.4) | ||
| Severe | 27 (6.3) | 22 (15.5) | 80 (18.4) |
Pearson χ2 test or Fisher’s Exact test.
BPD: bronchopulmonary dysplasia;
Figure 3Disability Status at 36 Months Corrected Age.
Proportional odds model of factors associated with neurodevelopmental disability.
| Predictors | p-value | Odds ratio (OR) for increasing disability |
| BPD with chronic oxygen dependency vs. No BPD | 0.013 | 1.8 (1.1 to 2.9) |
| BPD vs. No BPD | 0.022 | 1.9 (1.1 to 3.5) |
| BPD with chronic oxygen dependency vs. BPD | 0.755 | 0.9 (0.6 to 1.5) |
| Maternal Race (Non-Caucasian vs. Caucasian) | 0.005 | 1.8 (1.2 to 2.6) |
| Blood transfusions (per unit increase in no. of times) | 0.001 | 1.1 (1.1 to 1.2) |
| Postnatal steroids | 0.029 | 1.6 (1.1 to 2.5) |
| NEC | 0.017 | 1.9 (1.1 to 3.1) |
| IVH grade III or IV | <0.001 | 9.6 (5.0 to 18.8) |
| Gestational age (per 1 week increase) | 0.535 | 1.0 (0.9 to 1.1) |
*Estimated odds ratios from proportional odds model; odds of mild or severe disability versus no disability, and odds of severe disability versus milder or no disability; Score test for the proportional odds assumption: p = 0.149; Likelihood ratio test for overall model significance: p<0.001.
The model was first run with No BPD as the reference category. In order to obtain estimates for BPD with chronic oxygen dependency versus BPD, the model was run a second time, using BPD as the reference category.
BPD: bronchopulmonary dysplasia; NEC: necrotizing enterocolitis; IVH: intraventricular hemorrhage; SGA: small for gestational age; PDA: patent ductus arteriosus; RDS: respiratory distress syndrome; ROP: retinopathy of prematurity.
Language outcomes at 36 months corrected age.
| No BPD | BPD | BPD withchronic oxygendependency | Confidence Intervals forPairwise Differences | ||||
| Language | (n = 385/442) | (n = 135/144) | (n = 398/444) | p-value | No BPDvs. BPD | No BPD vs. BPDwith chronicoxygen dependency | BPD vs. BPDwith chronicoxygen dependency |
| Abnormal Overall Communication, no. (%) | 195 (51.1) | 80 (59.3) | 234 (59.4) | 0.053 | (−0.20 to 0.04) | (−0.17 to 0.01) | (−0.12 to 0.12) |
| Abnormal Receptive Language, no. (%) | 115 (32.9) | 48 (39.3) | 138 (39.3) | 0.163 | (−0.19 to 0.06) | (−0.15 to 0.02) | (−0.12 to 0.12) |
| Abnormal Expressive Language, no. (%) | 144 (41.6) | 55 (45.1) | 158 (44.8) | 0.654 | (−0.16 to 0.09) | (−0.12 to 0.06) | (−0.12 to 0.13) |
*Pearson χ2 test or Fisher’s Exact test.
Bonferroni correction applied to adjust for the three pairwise comparisons, thus confidence intervals are reported at the (1–0.05/3) % level.
BPD: bronchopulmonary dysplasia;